| Naslov: | Medications and cognitive decline in Alzheimer's disease : Cohort cluster analysis of 15,428 patients |
|---|
| Avtorji: | ID Grau-Jurado, Pol (Avtor)
ID Mostafaei, Shayan (Avtor)
ID Xu, Hong (Avtor)
ID Mo, Minjia (Avtor)
ID Petek, Bojana (Avtor)
ID Kalar, Irena (Avtor)
ID Naia, Luana (Avtor)
ID Kele, Julianna (Avtor)
ID Maioli, Silvia (Avtor)
ID Carvalho, Joana (Avtor)
ID Eriksdotter Jönhagen, Maria (Avtor)
ID Chatterjee, Saikat (Avtor)
ID Garcia-Ptacek, Sara (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,86 MB)
MD5: B24F11C914DCC570CAA40EA233E675CB
 URL - Izvorni URL, za dostop obiščite https://journals.sagepub.com/doi/full/10.1177/13872877241307870
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | BackgroundMedications for comorbid conditions may affect cognition in Alzheimer's disease (AD). ObjectiveTo explore the association between common medications and cognition, measured with the Mini-Mental State Examination. MethodsCohort study including persons with AD from the Swedish Registry for Cognitive/Dementia Disorders (SveDem). Medications were included if they were used by ≥5% of patients (26 individual drugs). Each follow-up was analyzed independently by performing 100 Monte-Carlo simulations of two steps each 1) k-means clustering of patients according to Mini-Mental State Examination at follow-up and its decline since previous measure, and 2) Identification of medications presenting statistically significant differences in the proportion of users in the different clusters. Results15,428 patients (60.38% women) were studied. Four clusters were identified. Medications associated with the best cognition cluster (relative to the worse) were atorvastatin (point estimate 1.44 95% confidence interval [1.15–1.83] at first follow-up, simvastatin (1.41 [1.11–1.78] at second follow-up), warfarin (1.56 [1.22–2.01] first follow-up), zopiclone (1.35 [1.15–1.58], and metformin (2.08 [1.35–3.33] second follow-up. Oxazepam (0.60 [0.50–0.73] first follow-up), paracetamol (0.83 [0.73–0.95] first follow-up), cyanocobalamin, felodipine and furosemide were associated with the worst cluster. Cholinesterase inhibitors were associated with the best cognition clusters, whereas memantine appeared in the worse cognition clusters, consistent with its indication in moderate to severe dementia. ConclusionsWe performed unsupervised clustering to classify patients based on their current cognition and cognitive decline from previous testing. Atorvastatin, simvastatin, warfarin, metformin, and zopiclone presented a positive and statistically significant associations with cognition, while oxazepam, cyanocobalamin, felodipine, furosemide and paracetamol, were associated with the worst cluster. |
|---|
| Ključne besede: | Alzheimer's disease, cohort study, comorbidity, metformin, Mini-Mental State Examination, oxazepam, pharmacological treatments, statins, warfarin, zopiclone |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 931–940 |
|---|
| Številčenje: | Vol. 103, issue 3 |
|---|
| PID: | 20.500.12556/DiRROS-28970  |
|---|
| UDK: | 616.894 |
|---|
| ISSN pri članku: | 1875-8908 |
|---|
| DOI: | 10.1177/1387287724130787 |
|---|
| COBISS.SI-ID: | 242978307 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 18. 7. 2025;
|
|---|
| Datum objave v DiRROS: | 15.04.2026 |
|---|
| Število ogledov: | 141 |
|---|
| Število prenosov: | 120 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
